PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10391138-6	1999	Poly ICLC treatment of infected mice caused no change in blood parasitaemia but resulted in a significant increase in GSH, glutathione reductase, SOD and catalase with respect to infected mice.	poly ICLC	0-9	glutathione reductase	Mus musculus	123-144
10391138-6	1999	Poly ICLC treatment of infected mice caused no change in blood parasitaemia but resulted in a significant increase in GSH, glutathione reductase, SOD and catalase with respect to infected mice.	poly ICLC	0-9	catalase	Mus musculus	154-162
1591717-16	1992	Poly-ICLC can be used to enhance IL-2-induced NK lytic activity without increases in the dose and, therefore, the toxicity of IL-2 treatment.	poly ICLC	0-9	interleukin 2	Homo sapiens	33-37
1591717-16	1992	Poly-ICLC can be used to enhance IL-2-induced NK lytic activity without increases in the dose and, therefore, the toxicity of IL-2 treatment.	poly ICLC	0-9	interleukin 2	Homo sapiens	126-130
34280415-6	2021	Here, we report that sHDL-Ag admixed with polyICLC elicited robust Ag-specific CD8+ T cell responses in mice, and when used in combination with alpha-PD-1 immune checkpoint inhibitor, sHDL-Ag + polyICLC completely eliminated large established (~100 mm3) MC-38 tumors in mice.	poly ICLC	42-50	CD8a molecule	Homo sapiens	79-82
2459270-1	1988	A preliminary trial of the interferon (IFN) inducer polyriboinosinic acid-polyribocytidylic acid in poly-L-lysine and carboxymethylcellulose (poly ICLC) was conducted in patients with chronic progressive multiple sclerosis (MS).	poly ICLC	142-151	interferon alpha 1	Homo sapiens	27-37
2459270-1	1988	A preliminary trial of the interferon (IFN) inducer polyriboinosinic acid-polyribocytidylic acid in poly-L-lysine and carboxymethylcellulose (poly ICLC) was conducted in patients with chronic progressive multiple sclerosis (MS).	poly ICLC	142-151	interferon alpha 1	Homo sapiens	39-42
31595804-2	2020	Polyriboinosinic polyribocytidylic acid [Poly (I: C)], a synthetic analog of viral double stranded RNA that can be recognized by Toll like receptor 3 (TLR3), was used to imitate virus infection.	poly ICLC	0-39	toll like receptor 3	Homo sapiens	151-155
33562773-9	2021	Furthermore, knockdown of PKR/OAS abrogated the anticancer action of Hiltonol, provoking survival of cancer cells.	poly ICLC	69-77	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	26-29
33562773-9	2021	Furthermore, knockdown of PKR/OAS abrogated the anticancer action of Hiltonol, provoking survival of cancer cells.	poly ICLC	69-77	SPARC related modular calcium binding 1	Homo sapiens	30-33
33562773-11	2021	Altogether, our findings unraveled the significance of studying tumor biobank tissues, which suggests PKR and OAS as precision oncological suppressor candidates to be targeted by this novel Hiltonol+++ cocktail which represents a prospective drug for development into a potent and tailored therapy for NSCLC subtypes.	poly ICLC	190-201	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	102-105
33562773-11	2021	Altogether, our findings unraveled the significance of studying tumor biobank tissues, which suggests PKR and OAS as precision oncological suppressor candidates to be targeted by this novel Hiltonol+++ cocktail which represents a prospective drug for development into a potent and tailored therapy for NSCLC subtypes.	poly ICLC	190-201	SPARC related modular calcium binding 1	Homo sapiens	110-113
33479025-2	2021	We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incomplete Freund"s adjuvant (IFA) would be safe and would support strong, durable CD4+ T cell and Ab responses.	poly ICLC	57-65	toll like receptor 3	Homo sapiens	28-48
33479025-2	2021	We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incomplete Freund"s adjuvant (IFA) would be safe and would support strong, durable CD4+ T cell and Ab responses.	poly ICLC	57-65	CD4 molecule	Homo sapiens	155-158
31595804-2	2020	Polyriboinosinic polyribocytidylic acid [Poly (I: C)], a synthetic analog of viral double stranded RNA that can be recognized by Toll like receptor 3 (TLR3), was used to imitate virus infection.	poly ICLC	0-39	toll like receptor 3	Homo sapiens	129-149
29950349-1	2018	Purpose: Polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC), a synthetic double-stranded RNA complex, is a ligand for toll-like receptor-3 and MDA-5 that can activate immune cells, such as dendritic cells, and trigger natural killer cells to kill tumor cells.Patients and Methods: In this pilot study, eligible patients included those with recurrent metastatic disease in whom prior systemic therapy (head and neck squamous cell cancer and melanoma) failed.	poly ICLC	79-88	toll like receptor 3	Homo sapiens	148-168
31742236-3	2019	In this context, we recently reported the effects of polyriboinosinic-polyribocytidylic acid-induced maternal immune activation at gestational day 15, immediately prior to birth, at gestational day 21 and again at post-natal day 21, providing a systematic assessment of plasma interleukin 6, body temperature and weight alterations in pregnant rats and preliminary evidence for gross morphological changes and microglial neuropathology in both male and female offsprings at these time points.	poly ICLC	53-92	interleukin 6	Rattus norvegicus	277-290
29950349-1	2018	Purpose: Polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC), a synthetic double-stranded RNA complex, is a ligand for toll-like receptor-3 and MDA-5 that can activate immune cells, such as dendritic cells, and trigger natural killer cells to kill tumor cells.Patients and Methods: In this pilot study, eligible patients included those with recurrent metastatic disease in whom prior systemic therapy (head and neck squamous cell cancer and melanoma) failed.	poly ICLC	79-88	interferon induced with helicase C domain 1	Homo sapiens	173-178
23928481-3	2013	Our method utilizes the synthetic TLR 3 agonist Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) to stimulate the DCs.	poly ICLC	118-127	toll like receptor 3	Homo sapiens	34-39
29205929-5	2018	First strong gag specific helper CD4+ T cells are induced in mice by selected targeting of anti-DEC205-gagP24 protein vaccine to dendritic cells (DC) in situ together with polyICLC as adjuvant.	poly ICLC	172-180	melanoma antigen	Mus musculus	13-16
24586996-8	2014	PolyICLC administration was associated with increases in TNFalpha, IL6, MCP1, MIP1alpha, KC, and MIP1beta levels in the periphery and with the activation of dendritic cells (DCs), NK cells, and B cells.	poly ICLC	0-8	tumor necrosis factor	Mus musculus	57-65
24586996-8	2014	PolyICLC administration was associated with increases in TNFalpha, IL6, MCP1, MIP1alpha, KC, and MIP1beta levels in the periphery and with the activation of dendritic cells (DCs), NK cells, and B cells.	poly ICLC	0-8	interleukin 6	Mus musculus	67-70
24586996-8	2014	PolyICLC administration was associated with increases in TNFalpha, IL6, MCP1, MIP1alpha, KC, and MIP1beta levels in the periphery and with the activation of dendritic cells (DCs), NK cells, and B cells.	poly ICLC	0-8	mast cell protease 1	Mus musculus	72-76
24586996-8	2014	PolyICLC administration was associated with increases in TNFalpha, IL6, MCP1, MIP1alpha, KC, and MIP1beta levels in the periphery and with the activation of dendritic cells (DCs), NK cells, and B cells.	poly ICLC	0-8	chemokine (C-C motif) ligand 3	Mus musculus	78-87
24586996-8	2014	PolyICLC administration was associated with increases in TNFalpha, IL6, MCP1, MIP1alpha, KC, and MIP1beta levels in the periphery and with the activation of dendritic cells (DCs), NK cells, and B cells.	poly ICLC	0-8	chemokine (C-C motif) ligand 4	Mus musculus	97-105
24777970-0	2013	Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.	poly ICLC	24-33	CD4 molecule	Homo sapiens	80-83
24777970-8	2013	In summary, Montanide and poly-ICLC had distinct and cooperative effects for the induction of NY-ESO-1-specific Th1 cells and integrated immune responses by OLP vaccination.	poly ICLC	26-35	cancer/testis antigen 1A	Homo sapiens	94-102
29696308-5	2018	Poly-ICLC was shown to be more effective than poly-IC in generating type-I interferon (IFN-I) in various DC subsets, through its enhanced ability to escape the endosomal compartment and stimulate MDA5.	poly ICLC	0-9	interferon induced with helicase C domain 1	Mus musculus	196-200
26564103-6	2016	METHODS: Toll-like receptor 3, melanoma differentiation-associated protein 5-, and IFN-promoter stimulator 1-deficient mice were treated with poly-ICLC 24 hours before middle cerebral artery occlusion.	poly ICLC	142-151	toll-like receptor 3	Mus musculus	9-108
23894722-9	2013	Poly-ICLC plus cetuximab also induced a robust upregulation of CD80, CD83 and CD86 on the surface of DCs, a process that was partially NK-cell dependent.	poly ICLC	0-9	CD80 molecule	Homo sapiens	63-67
23894722-9	2013	Poly-ICLC plus cetuximab also induced a robust upregulation of CD80, CD83 and CD86 on the surface of DCs, a process that was partially NK-cell dependent.	poly ICLC	0-9	CD83 molecule	Homo sapiens	69-73
23894722-9	2013	Poly-ICLC plus cetuximab also induced a robust upregulation of CD80, CD83 and CD86 on the surface of DCs, a process that was partially NK-cell dependent.	poly ICLC	0-9	CD86 molecule	Homo sapiens	78-82
23209321-6	2013	Treatment of infected mice with a complex of polyinosinic-polycytidylic acid with poly-L-lysine and carboxymethyl cellulose (Hiltonol), a potent TLR3 agonist, significantly improved survival of both WT and IRAK4(KDKI) mice, thereby providing a potential treatment strategy in both normal and immunocompromised patients.	poly ICLC	125-133	toll-like receptor 3	Mus musculus	145-149
23209321-6	2013	Treatment of infected mice with a complex of polyinosinic-polycytidylic acid with poly-L-lysine and carboxymethyl cellulose (Hiltonol), a potent TLR3 agonist, significantly improved survival of both WT and IRAK4(KDKI) mice, thereby providing a potential treatment strategy in both normal and immunocompromised patients.	poly ICLC	125-133	interleukin-1 receptor-associated kinase 4	Mus musculus	206-211
23032745-7	2012	NY-ESO-1-specific antibody and CD8(+) T cells were undetectable after vaccination with OLP alone, but were found in 6 of 13 (46%) and 8 of 13 (62%) patients, respectively, after vaccination with OLP+Montanide, and in 10 of 11 (91%) and 10 of 11 (91%) patients, respectively, after vaccination with OLP+Montanide+Poly-ICLC.	poly ICLC	312-321	cancer/testis antigen 1A	Homo sapiens	0-8
23032745-9	2012	Inclusion of Poly-ICLC as an adjuvant further accelerated the induction of NY-ESO-1-specific immune responses.	poly ICLC	13-22	cancer/testis antigen 1A	Homo sapiens	75-83
21149657-1	2011	PURPOSE: A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel vaccination with alpha-type 1 polarized dendritic cells (alphaDC1) loaded with synthetic peptides for glioma-associated antigen (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2(+) patients with recurrent malignant gliomas.	poly ICLC	353-362	alpha glucosidase	Homo sapiens	197-228
20549206-2	2010	In this study, we sought to determine critical roles of host IFN-alpha and IFN-gamma pathways in the enhanced therapeutic efficacy mediated by peptide vaccines and polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in the murine central nervous system (CNS) GL261 glioma.	poly ICLC	257-266	interferon gamma	Mus musculus	75-84